Get the Stockscreener App
99.36
0.52%
0.51
After Hours:
99.36
Protagonist Therapeutics Inc stock is traded at $99.36, with a volume of 504.96K.
It is up +0.52% in the last 24 hours and down -2.67% over the past month.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$98.85
Open:
$98.51
24h Volume:
504.96K
Relative Volume:
0.69
Market Cap:
$6.39B
Revenue:
$46.02M
Net Income/Loss:
$-130.15M
P/E Ratio:
-48.64
EPS:
-2.0427
Net Cash Flow:
$56.08M
1W Performance:
+1.01%
1M Performance:
-2.67%
6M Performance:
+24.92%
1Y Performance:
+126.23%
1-Day Range:
$97.00
$100.15
1-Week Range:
$97.00
$105.03
52-Week Range:
$42.85
$107.84
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
99.36 | 6.39B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics price target raised to $130 from $125 at Citi - TipRanks
Nan Fung Trinity HK Ltd. Has $15.78 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Insider sales at PTGX (NASDAQ: PTGX) — 48,000 shares disclosed (05/07/2026) - Stock Titan
PTGX PE Ratio & Valuation, Is PTGX Overvalued - Intellectia AI
Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors - Sahm
Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS Forecasts - Yahoo Finance
PTGX: Upcoming Virtual Meeting to Engage Investors - GuruFocus
[144] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
PTGX (NASDAQ) Form 144: Insider notice to sell 12,000 shares - Stock Titan
Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Hold Rating, Raises Target Price to $110 - Moomoo
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge? - Yahoo Finance
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $117 - Moomoo
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $100 to $137 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00 - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Vanguard Group Inc. Purchases 1,156,461 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Citizens JMP Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $137 - Moomoo
Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com Nigeria
Citizens raises Protagonist Therapeutics stock price target on platform validation By Investing.com - Investing.com South Africa
Protagonist Therapeutics: Q1 Earnings Snapshot - Barchart.com
Protagonist Therapeutics, Inc. Q1 2026 Financial Report – SEC Filing, Balance Sheets, and Management Discussion - Minichart
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPS - MarketBeat
Protagonist Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Milestones and Takeda opt-out reshape Protagonist (NASDAQ: PTGX) outlook - Stock Titan
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist (NASDAQ: PTGX) posts Q1 profit amid ICOTYDE approval and $200M rusfertide opt-out - Stock Titan
Protagonist Therapeutics set to report as blockbuster bets grow By Investing.com - Investing.com Canada
Protagonist Therapeutics set to report as blockbuster bets grow - Investing.com India
MSN Money - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock - Insider Monkey
331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLC - MarketBeat
M&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
PTGX SEC FilingsProtagonist Ther 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard shows 5.09% stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Pictet Asset Management Holding SA Has $46.26 Million Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Vanguard reports 3.53M-share stake in Protagonist Therapeutics (NASDAQ: PTGX) - Stock Titan
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating - Moomoo
Blood cancer drug translates into $200 million payday for Bay Area company — and there's more to come - The Business Journals
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Moody Aldrich Partners LLC - MarketBeat
UBS Group AG Acquires 874,013 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
[ARS] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Protagonist Therapeutics (NASDAQ: PTGX) plans 2026 meeting and expanded equity plan - Stock Titan
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Takeda (TAK) and Protagonist Therapeutics Deal Revisited - GuruFocus
Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical - marketscreener.com
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):